Did Alpha Teknova beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Alpha Teknova next quarter?

What were the key takeaways from Alpha Teknova's earnings call?

What guidance did Alpha Teknova's management provide for the next earnings period?

What is Alpha Teknova's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Alpha Teknova year over year?

What factors drove the changes in Alpha Teknova's revenue and profit?

What does Alpha Teknova do and what are its main business segments?

- **Revenue Resilience**: Q3 2025 revenue up 9% YoY, driven by 16% growth in Lab Essentials. 75% of revenue from non-biopharma segments growing in low double digits, offsetting biopharma softness.
- **Operational Excellence**: Gross margin 30.7% (30.7% vs. 0.9% YoY, ex-charges). 70% of incremental revenue flowing to gross profit. 2026 automation projects to enhance scalability to $200M+.
- **Strategic Focus**: Continued investment in AI and RUO Plus initiative (161 customers) driving GMP migration. 2026 modest growth in custom biopharma (25% of revenue) vs. 75% from stable segments.
- **Financial Health**: Adjusted EBITDA improving to -$1.6M Q3 2025. No capital needs; free cash flow stable at $2.4M/Q. Reiterate 2025 guidance of $39M-$42M revenue.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue of $10.5M, up 9% YoY, driven by 16% growth in Lab Essentials products. This marks the fifth consecutive quarter of year-over-year growth.
- **Operational Efficiency**: Improved on-time delivery and investments in automation (e.g., electronic batch records, high-throughput dispensing lines) expected to enhance scalability. Management targets >$200M annualized revenue without significant capital investment.
- **Market Strategy**: 75% of revenue from non-biopharma segments (e.g., animal health, diagnostics) growing in low double digits. 25% from biopharma custom products, which face macroeconomic headwinds but show sequential improvement.
- **AI and Innovation**: Continued investment in AI to optimize pricing and supply chain, with gross margin improvements expected in 2026.

**【CFO Financial Commentary】**
- **Financial Performance**: GAAP net loss of $4.3M (-$0.08 EPS) vs. $7.6M (-$0.15 EPS) YoY. Non-GAAP metrics show progress: adjusted EBITDA improved to -$1.6M from -$2.2M YoY. Gross margin 30.7% (up from 0.9% YoY, excluding one-time charges).
- **Cash Flow**: Free cash outflow of $2.4M (same as Q3 2024). Ending cash of $22.1M, with no immediate capital needs despite reiterating 2025 revenue guidance of $39M-$42M.
- **Growth Drivers**: 70% of incremental revenue expected to flow to gross profit. Operating expenses to remain at least $8M/Q4, positioning for EBITDA positivity at $50M-$55M revenue.

**【Q&A Highlights】**
- **Market Trends**: Biopharma funding environment remains cautious, but 75% of revenue from less-impacted segments (e.g., RUO Plus initiative) shows resilience. RUO Plus customers migrating to GMP, supporting long-term growth.
- **Product Mix**: Increased demand for tools and diagnostics in non-biopharma segments. Gene therapy customers (39 of 48 clinical solutions) show mixed progress, but 23 focus on mRNA/gene therapy with potential for onshoring benefits yet to materialize.
- **Efficiency Initiatives**: 2026 projects (e.g., larger batch sizes) to reduce costs. Commercial headcount increases limited to <10 in 2026, focusing on process optimization over headcount expansion.
- **Customer Acquisition**: Clinical solutions customers up YoY, with focus on non-biopharma segments. 25% of revenue from custom biopharma expected to grow modestly, while 75% from catalog/custom products grows low double digits.

Alpha Teknova, Inc. (TKNO) Q3 2025 Earnings Call Transcript

- **Revenue Beat**: Q2 2025 revenue $10.3M (+7% YoY), driven by 32% Clinical Solutions growth and 12% trailing 12-month catalog growth.
- **Profitability Breakthrough**: Adjusted EBITDA -$0.8M (best since 2021), gross margin 38.7% (vs. 29.2% Q2 2024).
- **Strategic Momentum**: 48 clinical customers (vs. 13 in 2020), 60+ therapies in pipeline, and 15/16 quarters beating estimates since IPO.
- **Growth Catalysts**: New manufacturing facility, RUO+ initiative, and inorganic expansion into upstream reagents.
- **Financial Strength**: $24M cash, no capital raise needed, 2025 revenue guidance $39-42M.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 revenue increased 7% YoY to $10.3 million, driven by low double-digit growth in catalog products (60% of revenue) and 32% growth in Clinical Solutions. Adjusted EBITDA improved to -$0.8 million, the best quarterly result since 2021.
- **Operational Efficiency**: New manufacturing facility enables custom reagent delivery in weeks vs. months, supporting 48 clinical customers (up from 13 in 2020). Gross margin improved to 38.7% (vs. 29.2% Q2 2024) due to cost reductions and efficiency gains.
- **Strategic Focus**: 15 out of 16 quarters beating revenue estimates since IPO. Long-term strategy emphasizes catalog product leadership and custom reagent support for emerging therapies, with 60+ therapies in pipeline.
- **Inorganic Growth**: Exploring collaborations and tuck-in acquisitions to expand bioprocessing workflows, targeting upstream reagents like cell culture media and transfection reagents.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Lab Essentials ($7.8M, +2% YoY), Clinical Solutions ($2.1M, +32% YoY). Catalog products grew 12% trailing 12 months, above historical 12% average.
- **Profitability**: Gross margin 38.7% (vs. 29.2%), operating expenses down 5% to $7.4M. Free cash flow negative $2.3M (vs. -$3.0M) due to one-time $0.4M loss contingency settlement.
- **Guidance**: 2025 revenue $39-42M (7% growth). Gross margin target low 30s, EBITDA positive at $50-55M revenue. Free cash outflow < $12M.
- **Liquidity**: $24M cash, no capital raise needed for organic growth.

**【Q&A Key Highlights】**
- **Market Conditions**: Small/mid biotech customers facing funding challenges, but clinical customers (+48 vs. 13 in 2020) offset weakness. Later-stage therapies continue spending despite macro headwinds.
- **RUO+ Initiative**: Bridging preclinical to clinical with GMP-like manufacturing, enabling faster scale-up. Customers using RUO+ see 30x spend increase upon commercialization.
- **Gross Margin Outlook**: Q2 39% margin driven by one-time factors; expect low 30s for 2025. Long-term 70% incremental margin target remains.
- **Customer Spend**: 60% of revenue from >3,000 catalog accounts, 25% from custom biopharma. Large pharma and life science tools driving Q2 catalog growth.
- **Inorganic Strategy**: Seeking tuck-ins to expand upstream reagents (cell culture media, transfection) and leverage existing infrastructure.

Alpha Teknova (TKNO)-7 Aug 25-2025 Q2 Earnings call transcript

- **Q1 2025 Strong Start**: 5% revenue growth to $9.8M, 30.7% gross margin, and 12% Lab Essentials growth despite macro challenges.
- **Clinical Growth Strategy**: 48 clinical accounts (23 cell/gene therapy) targeting 15%+ annual growth, with PluriFreeze collaboration poised for long-term upside.
- **Financial Resilience**: $26.3M cash, 9% opex reduction, and no capital raise needed despite $4.6M net loss.
- **Strategic Differentiation**: Minimal geopolitical risk, exclusive PluriFreeze distribution, and focus on essential research tools for biotech recovery.

**【CEO Opening Remarks】**
- **Strong Q1 Performance**: Revenue grew 5% YoY to $9.8M, driven by catalog products (low double-digit growth) and clinical solutions (mid-single-digit growth excluding a large one-time order). Gross margin improved to 30.7% from 23.8% YoY.
- **Diversified Customer Base**: <4% of revenue from academic/government institutions, 95% from U.S. sales, and no China exposure. Tariff impact minimal, but biotech funding cuts may delay small/mid biotech purchases.
- **Growth Strategy**: Expand clinical customer base (48 accounts in 2024, 23 in cell/gene therapy) and target 15-25% annual growth. Launched PluriFreeze cryopreservation products with Pluristics, exclusive U.S./Canada distributor, with potential long-term upside.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Lab Essentials ($8.1M, +12%), Clinical Solutions ($1.2M, -32% due to one-time order). Adjusted EBITDA: -$2.5M (vs. -$3.8M YoY). Free cash flow: -$4.3M (vs. -$6.7M YoY).
- **Profitability**: Gross margin 30.7%, operating expenses down 9% YoY to $8.0M (excluding one-time severance). 2025 guidance: $39-42M revenue, high 20s% gross margin, $8M+ quarterly opex.
- **Liquidity**: $26.3M cash, $13.2M debt. No capital raise needed for organic growth.

**【Q&A Highlights】**
- **FDA Changes & Biotech Funding**: CEO expects cautious spending from small/mid biotechs but notes 2025 clinical solutions growth guidance remains intact. PluriFreeze launch at ASGCT shows early interest, but material impact likely 2026+.
- **Customer Mix & Utilization**: 48 clinical accounts (23 cell/gene therapy) with 30x+ spend increase from Phase I to commercialization. Newer customers lower near-term rev per customer, but long-term growth potential.
- **Collaboration Economics**: CFO confirms collaboration is EBITDA-positive, with exclusive manufacturing/distribution rights. CEO highlights PluriFreeze's viscosity reduction advantage for allogeneic therapies and broader RUO appeal.
- **Market Positioning**: Minimal exposure to NIH cuts (4% revenue), focus on essential research tools. FDA shifts to non-animal models could benefit organoid/3D cell culture product portfolio.


Alpha Teknova (TKNO)-8 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: 2024 total revenue $37.7M (+11% adjusted YoY), driven by biopharma segment (+40%). 2025 guidance: $39-42M (7% midpoint growth).
- **Cost Efficiency**: Operating expenses reduced $8.1M, free cash outflow improved to -$13.5M annually. 2025 free cash outflow guidance: <$12M.
- **Market Recovery**: Biopharma segment expected +15% in 2025 despite near-term macro uncertainty. Q1 2025 likely lowest quarter, with sequential improvement.
- **Customer Expansion**: 48 clinical customers (34 in 2023), 27% revenue from cell/gene therapy. New customers take 1-1.5 years to reach $100k+ annual spend.

**【CEO Summary Section】**
- **Revenue Growth and Market Recovery**: Total revenue reached $37.7 million in 2024, with adjusted growth of 11% excluding a large clinical order. North American market recovery and biopharma segment growth (40% YoY) drove momentum, though 2025 is expected to be a recovery year with 7% revenue growth guidance.
- **Customer Expansion and Product Launches**: Expanded clinical customers to 48 (from 34 in 2023), launched 3 new offerings (Build-Tek, Express-Tek, RUO+), and maintained service levels despite reduced headcount. 27% of revenue now comes from cell and gene therapy customers.
- **Cost Management and Cash Flow**: Reduced operating expenses by $8.1 million (excluding non-recurring charges) and improved free cash outflow to $13.5 million annually (vs. $26.7 million in 2023). Aged $30.4 million in cash and extended credit facility maturity to 2030.

**【CFO Financial Commentary】**
- **Revenue Performance**: Q4 2024 revenue $9.3 million (+18% YoY), full year $37.7 million (+3% YoY). Clinical Solutions revenue grew 76% excluding a 2023 outlier, while Lab Essentials remained stable at $28.9 million.
- **Gross Margin and Operating Expenses**: Full-year gross margin 19.2% (28.1% in 2023) due to inventory charges and higher overhead. Operating expenses decreased 23% to $33.4 million, with headcount reduced to 173 (from 211 in 2023).
- **Profitability and Cash Flow**: Net loss $26.7 million (-57% YoY), adjusted EBITDA -$14.5 million (improved from -$19.8 million). Free cash outflow guidance for 2025 is <$12 million, with 70% marginal cash conversion on incremental revenue.

**【Q&A Key Takeaways】**
- **Market Softness**: Biopharma customers delaying orders due to macroeconomic uncertainty, particularly smaller biotechs. 2025 biopharma segment growth expected at 15% despite near-term cautiousness.
- **Customer Ramp-Up**: New clinical customers take 1-1.5 years to reach $100k+ annual spend. Pricing increases implemented at mid-single digits in 2025.
- **2025 Outlook**: Q1 likely lowest quarter, with sequential improvement. Life science tools/diagnostics segment expected to recover mid-single digits after challenging 2024 comparisons.

TKNO

TKNO fundamentals

Earnings Call

You can ask Aime